gst-hg151
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 7, 2022 (NCT05345964)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- p38 MAP kinase alpha/betaACTIVATOR
p38 MAP kinase alpha/beta activator
MAP2K4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05345964 | Phase 1 | Mar 7, 2022 | Fujian Cosunter Pharmaceutical Co. Ltd, Fujian Medical University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fujian Cosunter Pharmaceutical Co. Ltd | For profit | 1 | 1 | 1 | 2022 |
| Fujian Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1